Post ASH 2022: Acute Myeloid Leukemia

Review Article

Haema 2023; 14(1-4):6-10

Michael D. Diamantidis1, George Vassilopoulos2

1Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, Larissa, Greece
2University of Thessaly Medical School, Head, Division of Hematology, Larisa University Hospital, Affiliate Investigator, Cell and Gene Therapy Lab, BRFAA Athens, Greece

 

Full PDF |

Continue reading “Post ASH 2022: Acute Myeloid Leukemia”

Post ASH 2022: Key studies in chronic lymphocytic leukemia (CLL)

Review Article

Haema 2023; 14(1-4):16-20

Eleftheria Hatzimichael,1,2 Epameinondas Koumpis1, Elisavet Apostolidou1

1Department of Haematology, University Hospital of Ioannina
2Faculty of Medicine, School of Health Sciences, University of Ioannina

 

Full PDF |

Continue reading “Post ASH 2022: Key studies in chronic lymphocytic leukemia (CLL)”

Post ASH 2022: Acute Myeloid Leukemia

Review Article

Haema 2023; 14(1-4):6-10

Michael D. Diamantidis1, George Vassilopoulos2

1Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, Larissa, Greece,
2University of Thessaly Medical School, Head, Division of Hematology, Larisa University Hospital, Affiliate Investigator, Cell and Gene Therapy Lab, BRFAA Athens, Greece

 

Full PDF |

Continue reading “Post ASH 2022: Acute Myeloid Leukemia”

The Role of Venetoclax in the Treatment of Acute Myeloid Leukemia

Review Article

Haema 2022; 13(1-2):20-30

Maria Dimou

Hematology Clinical Trial Unit, Hematology and Bone Marrow Transplantation Clinic, National and Kapodistrian University of Athens, Greece

Full PDF |

Continue reading “The Role of Venetoclax in the Treatment of Acute Myeloid Leukemia”